Primary gastrointestinal DLBCL (pGI-DLBCL) has a significantly decreased level of MYD88 and CD79B mutations compared to nodal DLBCL and other extranodal DLBCL in immune-privileged sites, such as central nervous system and testis [13, 14]. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.